{"entity":{"id":"nct03816163","kind":"trial","name":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of Zolbetuximab and Gemcitabine in pancreatic ductal adenocarcinoma, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.","summary":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer is a phase 2 interventional study registered as NCT03816163 by Astellas Pharma Global Development, Inc., with 393 participants enrolled, started 2019-03-15 and due to reach its primary completion in 2026-08-31. Interventions recorded: zolbetuximab, nab-paclitaxel and gemcitabine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03816163","url":"https://clinicaltrials.gov/study/NCT03816163"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["zolbetuximab","gemcitabine"],"companies":["astellas"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03816163","phase":"2","setting":"A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma","sponsor":"Astellas Pharma Global Development, Inc.","enrolled":393,"outcomes":[]},"route":"/trials/nct03816163/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/"}],"company":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/"}]}}